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Abstract
Background: Lymphatic filariasis has been identified as one of the six diseases that can be potentially
eliminated. Global programme to eliminate lymphatic filariasis has been launched, applying principal
strategies of mass drug administration to interrupt transmission and morbidity management to prevent
disability. The strategy for mass drug administration has been clearly laid out and guidelines have been well
documented for implementation, monitoring and evaluation of the programme but such a guideline is
warranted for morbidity management and disability prevention activities.
Discussion: Health Related Quality of Life, a multidimensional construct referring to patients' perceptions
of the impact of disease and treatment on their physical, psychological and social function and well being
is crucial in the evaluation of health care interventions. Lymphatic filariasis has a wide clinical spectrum and
disability is more pronounced in the advanced stages of lymphoedema and hydrocele. Since the advanced
stages of lymphoedema are not reversible, morbidity management and disability prevention activities can
lessen the disabilities due to secondary infections and there by improve the quality of life of the patient.
Thus, an improvement in quality of life is considered to be important as a primary outcome in the
determination of therapeutic benefit. Therefore it can be used as an indicator to assess the impact of
morbidity management and disability prevention activities in global programme to eliminate lymphatic
filariasis.
Summary: Disease specific Health Related Quality of Life instrument can be used to measure the
longitudinal changes in quality of life of patients following the intervention. High responsiveness, clinical
relevance to patients and its sensitiveness to detect small changes are the merits of disease specific
instrument. Morbidity management and disability prevention activities under filariasis elimination
programme aim at improving the quality of life of patients with irreversible manifestations. Therefore there
is an urgent need to develop an instrument to assess the health related quality of life, specific for lymphatic
filariasis by incorporating all the difficulties and problems caused to patients by the disease in the physical,
mental and social domains of health.
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Lymphatic Filariasis is an important public health prob-
lem in many tropical and sub-tropical countries. Globally,
1.3 billion people are at risk of infection and about 120
million people are affected in 83 countries [1]. This dis-
ease causes an estimated annual burden of 5.77 million
DALYs [2] in its endemic countries. The Global Pro-
gramme for the Elimination of Lymphatic Filariasis
(GPELF) was established in early 2000 following the
World Health Assembly Resolution 50.29 [3] in 1997. The
GPELF has 2 components. First is to interrupt the trans-
mission of infection through Mass Drug Administration
(MDA) with Diethylcarbamizine (DEC) or co-administra-
tion with Albandazole. Second is to reduce LF-related dis-
ability in those, already affected by chronic
manifestations of the disease through Morbidity Manage-
ment and Disability Prevention Activities (MMDPA).
MMDPA includes basic limb hygiene, which can prevent
secondary infections causing the acute episodes (Adenol-
ymphangitis) among lymphoedema patients, and surgical
corrections for hydrocele cases. [4]. GPELF has launched
MDA in 42 of the 83 endemic countries covering a popu-
lation of 610 million in 2005. Rest of the 8 countries may
not require MDA and 33 countries have not yet imple-
mented the programme [1]. However, the morbidity man-
agement activity, the second component of the GPELF
strategy is lagging [5]. Out of 83 endemic countries, only
27 have initiated the morbidity management programme
[1]. To date, the primary focus of the GPELF has been on
the chemotherapeutic interventions, that is MDA. The
strategy for MDA has been clearly laid out and guidelines
are well documented for implementation, monitoring
and evaluation of the programme [6]. However the guide-
lines for monitoring and evaluation have not yet been for-
mulated or standardized for the MMDPA. Hence there is
an urgent need to develop the strategy and guidelines for
monitoring and evaluating the MMDPA programme.
Discussion
Although GPELF programme has gathered momentum,
there are some issues to be resolved for achieving the
desired results of the programme. One among them is the
low priority given to morbidity management programme.
The reason for this may be the limited availability of
resources including trained personnel and surgical facili-
ties for performing hydrocelectomies. The strategy for
MDA has been clearly laid out and guidelines are available
for monitoring and evaluating the MDA programme and
are being followed by the implementing countries. The
epidemiological indicators such as microfilaria (mf) prev-
alence and mf density levels are used to assess the impact
of MDA programme [7]. Ultimately absence of transmis-
sion is verified using antigenemia in children. However,
the guidelines for monitoring and evaluating the morbid-
ity management programme have not yet been formu-
lated or standardized and as of now no indicators/tools
are available to assess the impact of morbidity manage-
ment. The World Health Organization (WHO) has pro-
posed to develop an instrument based on International
Classification of Functioning, Disability and Health (ICF) and
WHO Disability Assessment Schedule (WHODAS) [8] for
assessing the impact of chronic disabling diseases like LF,
leprosy, diabetes etc. The WHODAS was developed build-
ing on the experience of existing instruments developed to
assess health and disability. It is a general health state
assessment measure that can be used in epidemiological
surveys, health systems research such as the evaluation of
needs and outcomes, clinical assessment and as a poten-
tial descriptive system for Summary Measures of Popula-
tion Health (SMPH). It gives a general disability score as
well as different profiles on health domains like cogni-
tion, mobility, self-care, interpersonal relations and par-
ticipation in community. However there are constraints in
using WHODAS as an assessment tool for evaluating
MMDPA for LF. It is a general health state assessment
instrument and thereby ignores the entanglement of dis-
eases and their signs or symptoms. Since the disabilities
due to LF are dependent on its particular health state, this
instrument may not be suitable to assess the impact of
intervention programmes on LF. Further, MMDPA aims at
improving the quality of life and therefore it is ideal to
develop an instrument, which can measure the quality of
life.
There is an increasing recognition that what matters most
to patients is how well they are able to function in their
day-to-day life [9] and the self-reported health status is
receiving increasing attention in epidemiological and out-
comes research [10]. Understanding the impact of chronic
illness on functioning and well being in physical, mental
and social dimensions of life have become essential and
therefore efforts to incorporate quality of life in medical
care outcome studies are increasing [11]. Health Related
Quality of Life (HRQoL), a multidimensional construct
referring to patients' perceptions of the impact of disease
and treatment on their physical, psychological and social
function and well being [12] is crucial in the evaluation of
health care interventions [13]. LF has a wide clinical spec-
trum [14] and disability is more pronounced in the
advanced stages of lymphoedema and Hydrocele. Since
the advanced stages of lymphoedema are not reversible,
MMDPA can lessen the disabilities due to secondary infec-
tions and there by improve the quality of life of the
patient. Thus, an improvement in quality of life is consid-
ered to be important as a primary outcome in the determi-
nation of therapeutic benefit.
The concept of HRQoL is used as an important parameter
for measuring outcome in modern medicine. This can be
used as discriminative as well as an evaluative indicator.Page 2 of 4
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assess the impact of MMDPA in GPELF. HRQoL can be
measured using both generic and disease specific instru-
ments [15]. Generic instrument assesses general aspect of
HRQoL that are applicable to any disease or health condi-
tions but lacks sensitivity to detect the changes after the
intervention, whereas the disease specific instrument
assess the particular concerns and conditions related to
that particular disease or health state [16] and so is more
sensitive to detect the changes between pre and post inter-
vention period. Disease specific measures are most appro-
priate because of their higher responsiveness and their
outcomes will be clinically relevant to the patient. In LF,
disability is more pronounced in the advanced stages of
lymphoedema and hydrocele. While disability due to
hydrocele can be reverted through surgery, disability due
to the advanced stages of lymph oedema is not reversible
and hence disability due to these health states cannot be
reduced. However it is possible to prevent secondary bac-
terial infections leading to ADL attacks through simple
home-based approaches like leg hygiene and simple exer-
cises. These measures will reduce the frequency of ADL
attacks and thereby improve the quality of life of the
patients. A generic instrument may not be able to capture
all the items, which are potentially affecting their quality
of life including the specific disabling signs and symptom
of LF. Therefore it is suggested that LF specific instruments
be utilized for assessing the impact. Since the disease spe-
cific HRQoL instruments are not available for LF, there is
an urgent need to develop such a valid and reliable instru-
ment to assess the impact of morbidity management pro-
gramme.
Summary
Guidelines for ELF programme implementation and
monitoring are necessary for the programme managers at
different levels. Such guidelines are already available for
MDA, but warrant one for MMDPA. Monitoring the
impact of intervention is an inbuilt component of the pro-
gramme and is essential to assess the progress and end-
points. Though WHODAS has been recommended as a
generic instrument, it can not be considered as more
appropriate. HRQoL can be used as an indicator to assess
the impact of MMDPA and LF specific HRQoL instrument
(LF-QoL) is appropriate, as it can be developed to assess
the health outcome in terms of quality of life. MMDPA
aims at reducing the morbidity and improving the quality
of life of chronic patients, which is irreversible. This is not
only useful to assess the effect of home management to
prevent secondary infection and progression of disease,
but also to assess the impact of surgical corrections of
hydrocele patients. LF-QoL can be developed following
standard methods described elsewhere [12,16]. All the
difficulties and problems caused to patients by the disease
in the physical, mental and social domains can be incor-
porated in developing the questionnaire. As the morbidity
pattern and response to morbidity varies with the type of
manifestation, it is necessary to assess the HRQoL for dif-
ferent clinical manifestations of LF by LF-QoL instrument.
Similar assessment can be done following the morbidity
management interventions and the outcome can be com-
pared prior to and after the intervention. This will indicate
the level of improvement in the quality of life following
the intervention because disease specific HRQoL measure
is more sensitive to detect the changes between pre and
post intervention period. MMDPA has not yet received
much priority/attention by the programme managers as
only 27 out of 83 endemic countries have initiated this
programme. The primary focus of programme managers
has been on to scaling up MDA to cover all at-risk popu-
lations. The countries implementing MDA to interrupt the
transmission of filarial parasite should also establish pro-
grammes to implement the morbidity management to
prevent LF related disability to achieve the overall objec-
tive of GPELF by the year 2020.
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